This paper examines the role of patents in the pharmaceutical industry, analyzing how intellectual property rights protect drug manufacturers under frameworks such as the TRIPS agreement while simultaneously creating barriers to affordable medicine. It explores why the pharmaceutical sector is especially vulnerable to piracy and counterfeiting, connecting high profit margins and low marginal production costs to the incentive for generic manufacturers to enter the market. The paper also assesses potential responses available to pharmaceutical companies — including authentication technologies — and argues that targeted government intervention focused on consumer education and regulatory compliance offers a more balanced path forward than simple enforcement alone.
Intellectual property theft through piracy and counterfeiting has risen dramatically over the last couple of decades. As a result, both the level of activity and the organizational scale of pirates and counterfeiters have increased significantly. The pharmaceutical industry has been widely affected; more than 90% of donor-funded HIV medicines in the market today are generic (ITPC Factsheet, n.d., p. 1). Patents are a major instrument in the enforcement of intellectual property rights.
A patent on a drug gives the owner — in this case, the inventing pharmaceutical company — the exclusive right to prevent others from making, using, importing, or selling it (Elliott & Bonin, 2002, p. 1). Intellectual property law was incorporated into the global trading system with the passage of the TRIPS (Trade-Related Aspects of Intellectual Property Rights) agreement, which offers protection to the patent rights of pharmaceutical entities by prohibiting generic companies from manufacturing patented drugs (Elliott & Bonin, 2002).
The pharmaceutical, music, and software industries have been affected by piracy and counterfeiting more than any other sector. These are also among the most profitable industries in the world, well ahead of all other sectors (Elliott & Bonin, 2002). With regard to the pharmaceutical industry, the costs of production are high given the substantial research and development involved. However, fixed costs are offset by the fact that the industry operates on a global scale and enjoys massive economies of scale.
The variable costs, given the significance of the industry, are often covered by public subsidies through both direct government investment and tax breaks for research. This means that the marginal costs of production are relatively low, and hence the price-cost margin is significantly high. It is these high profit margins that attract new entrants in the form of counterfeiters and pirates. As in the model of perfect competition, competitiveness is determined by entrants' ability to replicate the incumbents' production.
"Corporate responses including authentication technology"
"Role of regulation, licensing, and consumer education"
The market system appears to have failed in resource allocation in this case, and the government ought to intervene further. This time, however, the focus should be on increasing consumer knowledge about generic products rather than simply on improving drug availability. On the same note, the government should put in place strict measures to ensure that generic manufacturers comply with regulations and do not imitate the authentication methods that distinguish legitimate drugs from generics — a matter closely related to compulsory licensing frameworks. With consumers better informed about the risks of generic substances, and branded products clearly distinguishable from generics, the market system will be better positioned to determine demand and supply and to allocate resources efficiently.
You’re 57% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.